52853
7α-Hydroxy-4-cholesten-3-one
≥95.0% (HPLC)
Synonym(s):
7α-Hydroxycholest-4-en-3-one
Sign Into View Organizational & Contract Pricing
All Photos(1)
Select a Size
Change View
1 MG
₩499,177
About This Item
Empirical Formula (Hill Notation):
C27H44O2
CAS Number:
Molecular Weight:
400.64
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24
Recommended Products
grade
analytical standard
Quality Level
Assay
≥95.0% (HPLC)
application(s)
clinical testing
format
neat
storage temp.
−20°C
SMILES string
O=C1CC[C@@]2(C)C(C[C@@H](O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@H](C)CCCC(C)C)=C1
InChI
1S/C27H44O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h15,17-18,21-25,29H,6-14,16H2,1-5H3/t18-,21-,22+,23+,24-,25+,26+,27-/m1/s1
InChI key
IOIZWEJGGCZDOL-RQDYSCIWSA-N
Related Categories
General description
7α-Hydroxy-4-cholesten-3-one (C4) is known as a marker for the cholesterol 7α-hydroxylase activity. It plays an important role in bile acid metabolism.[1]
Application
C4 may be used as a reference standard for the determination of C4 in:
- Human serum by ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) with electrospray ionization source (ESI)[2] as well as LC-MS.[1]
- Rat and monkey plasma by LC-ESI-MS/MS working on multiple reaction monitoring (MRM) mode of detection.[3]
- Peripheral blood plasma by solid-phase extraction (SPE) and HPLC.[4]
Biochem/physiol Actions
7a-Hydroxycholestene-3-one, a metabolite in bile acid synthesis, is derived from 7a-hydroxycholesterol and can be further metabolized to 7a,12a,-dihydroxycholest-4-en-3-one. Analysis of 7a-Hydroxycholestene-3-one (HCO) in serum may serve as a novel, simple, and sensitive method for the detection of bile acid malabsorption in patients with chronic diarrhea of unknown origin.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
LC-MS/MS quantification of 7?-hydroxy-4-cholesten-3-one (C4) in rat and monkey plasma.
Kang L, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications, 1064, 49-55 (2017)
Marcos Pedrosa et al.
Contemporary clinical trials, 88, 105889-105889 (2019-11-16)
Nonalcoholic steatohepatitis (NASH) is a multifactorial disease involving different contributing mechanisms, with no approved therapies so far. Tropifexor (TXR), a farnesoid X receptor agonist, and cenicriviroc (CVC), a chemokine receptor types 2/5 antagonist, target the steatotic, inflammatory, and/or fibrotic pathways
C G Hillebrant et al.
European journal of clinical investigation, 28(4), 324-328 (1998-06-06)
HMG-CoA reductase inhibitors are now the therapy of choice in the treatment of hypercholesterolaemia. The effects of long-term treatment with these substances on plasma lipoproteins, cholesterol metabolism and biliary secretion of lipids have been extensively studied in humans. Much less
Monitoring hepatic cholesterol 7?-hydroxylase activity by assay of the stable bile acid intermediate 7?-hydroxy-4-cholesten-3-one in peripheral blood.
Galman C, et al.
Journal of Lipid Research, 44(4), 859-866 (2003)
Michael K Badman et al.
Clinical pharmacology in drug development, 9(3), 395-410 (2019-12-12)
Tropifexor (LJN452) is a potent, orally available, non-bile acid farnesoid X receptor agonist under clinical development for chronic liver diseases. Here, we present results from a first-in-human study of tropifexor following single- and multiple-ascending doses (SAD/MAD) and food effect substudy
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
